This phase IV trial comprises men with metastatic castration-resistant prostate cancer who have previously received docetaxel and have experienced progression within 12 months of initiating androgen receptor-targeted therapy (abiraterone or enzalutamide). Participants receive either cabazitaxel or switch to the alternative androgen receptor-targeted agent as per random assignment.
The study results were presented at the ESMO Congress 2019, supporting cabazitaxel use in mCRPC.
Silke Gillessen comments on the CARD study (3:02):